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ABSTRACT OF THESIS 
ASSESSMENT OF THE SERUM AMYLOID A ASSAY FOR DIAGNOSING 
DISEASE IN NEONATAL FOALS 
Diagnosing disease in equine neonates poses a challenge for the equine industry 
because of the nonspecific manifestations of many diseases and the rapid deterioration 
that occurs.  The differential diagnostic procedure requires many laboratory tests, whose 
results take days to receive.  Serum amyloid A (SAA) is the only major acute phase 
protein identified in the horse; it exists in low levels in the healthy horse and increases 
over 100 fold in response to inflammatory stimulus 6-8 hours post stimulus. A point of 
care test allows veterinarians to obtain a SAA concentration within minutes that indicates 
the existence of infection.  Being able to test and quantify this protein at the onset of 
illness may reduce the time before treatment is initiated and therefore increase the chance 
of survival for the equine neonate, which would greatly help a large problem in the 
industry.  
KEYWORDS: equine neonate, neonatal disease, serum amyloid A, differential diagnosis, 
assay application  
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Overview 
 
 The first chapter of this thesis is a literature review that serves to provide the 
reader with a foundation of information that will prepare them for the work presented in 
the following chapters. The literature review presents background information on the 
concepts presented in the chapters that follow and summarizes the literature published 
regarding the topics related to the research projects presented.  
 The second chapter provides an introduction to the original studies that are 
presented in the later chapters of the thesis. It explains the rationale behind the thesis. 
Finally, it presents the specific hypotheses and objectives of each study. 
 The third and fourth chapters of the thesis present original studies in the form of 
manuscripts submitted to peer-reviewed journals.  They follow the style required by the 
specific journals to which they were, or will be, submitted.  Each chapter presents an 
abstract, introduction, materials and methods, results, and discussion and clinical 
relevance section.  
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Chapter One: Literature Review 
 
Assessing the application of measuring serum amyloid A (SAA) as a marker of 
disease in the equine veterinary practice 
 
 
Mortality and morbidity rates of sick equine neonates are a cause of concern in 
the equine clinical setting. Equine neonatal diseases can progress quickly and despite 
aggressive treatment, neonates often succumb to the rapid progression of disease and are 
unable to recover.  Diagnosing equine neonatal diseases based on clinical symptoms is 
difficult due to the nonspecific manifestations of many diseases; however, obtaining an 
accurate diagnosis within a critical time frame is essential to improving the prognosis of 
the patient. The following pages describe many common equine neonatal diseases that 
are diagnosed at equine veterinary hospitals as well as the diagnostic procedures and 
treatments commonly used to diagnose and treat these diseases.  
Pneumonia  
Lower respiratory tract infections are common in neonatal foals and are one of the 
leading causes of morbidity and mortality in equine neonates (Reuss and Cohen, 2015 
and McKenzie, 2006).  Pneumonia in neonates is most often associated with septicemia 
and can develop in utero or at the time of parturition (Reuss and Cohen, 2015 and 
McKenzie, 2006).  In utero it is possible to develop pneumonia due to infected fetal 
membranes or via aspirating contaminated fetal fluids (Reuss and Cohen, 2015). During, 
or shortly after, parturition, pneumonia can develop due to foreign microbes invading the 
bloodstream via the respiratory tract, gastrointestinal tract, or umbilicus (Reuss and 
Cohen, 2015). This invasion can result in systemic inflammatory response syndrome, 
which can manifest as generalized or localized clinical signs of sepsis including acute 
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lung injury or respiratory distress (Reuss and Cohen, 2015). While it is possible for 
mixed infections and gram-positive infections to occur, neonatal pneumonia is most often 
caused by gram-negative bacteria (McKenzie 2006). The most common gram-negative 
bacteria that causes neonatal pneumonia is Escherichia coli, but other bacteria that cause 
neonatal pneumonia include Klebsiella spp, Actinobacillus spp, and Salmonella spp 
(Reuss and Cohen, 2015). 
Pneumonia can develop secondary to meconium aspiration or milk aspiration in 
neonates (McKenzie, 2006). Meconium aspiration occurs in utero or during parturition 
(Reuss and Cohen, 2015). Meconium aspiration most commonly occurs due to 
mechanical airway obstruction, chemical pneumonitis, alveolar edema, or displacement 
of surfactant (Reuss and Cohen, 2015). Despite the meconium being sterile, bacterial 
pneumonia develops due to the compromised respiratory functions of the neonate (Reuss 
and Cohen, 2015). Milk aspiration most commonly occurs in neonates that have a weak 
suckle or dysphagia (Reuss and Cohen, 2015). Other causes of milk aspiration can 
include improper nasogastric feeding tube placement or improper bottle-feeding (Reuss 
and Cohen, 2015).  
Diagnosing neonatal pneumonia includes a comprehensive patient diagnostic 
evaluation. A physical exam including thorough auscultation of the thorax and a 
rebreathing examination is conducted (Reuss an Cohen, 2015). Thoracic radiographs 
provide information regarding the distribution and severity of the pneumonia as well as 
giving insight to the cause of the bacterial infection (Reuss and Cohen, 2015). 
Ultrasonography may be used to determine pathologic abnormalities in the pleural space 
(Reuss and Cohen, 2015). Comprehensive bloodwork, including white blood cell 
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concentration with a differential cell count, plasma fibrinogen, and globulin 
determination can provide insight into the severity of the disease and a blood culture 
should be obtained to identify the causative bacterial organism (Reuss and Cohen, 2015).  
Treatment of neonatal pneumonia involves a combination of antimicrobial, anti-
inflammatory, and ancillary therapies (McKenzie, 2006).  When determining which 
therapies to utilize, the veterinarian must consider the organisms involved, the severity or 
the illness, and the ability to administer the drug (McKenize, 2006). Because neonatal 
pneumonia is most commonly a result of septicemia, a broad-spectrum antimicrobial drug 
is used (McKenzie, 2006). Common antimicrobials used to treat neonatal pneumonia 
include -lactam antibiotics such as ceftiofur or ampicillin in combination with an 
aminoglycoside antimicrobial such as amikacin (Reuss and Cohen, 2015).  Once the 
results from the blood culture are obtained, it is possible to develop a more specifically 
targeted antimicrobial regimen. Nonsteroidal anti-inflammatory drugs are often included 
in a treatment plan to decrease fever and discomfort (McKenzie, 2006).  Supplemental 
oxygen is often provided to foals with neonatal pneumonia via nasal insufflation 
(McKenize, 2006). Other ancillary therapies include rest, temperature control, the use of 
bronchidilators, and the use of gastric acid suppressive drugs (McKenzie, 2006). While 
neonatal pneumonia can be a severe and deadly disease, recovery with proper treatment 
and management is possible and does not have a negative impact on performance later in 
life (Reuss and Cohen, 2015).     
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Hypoxic Ischemic Encephalopathy  
Hypoxic ischemic encephalopathy (HIE) is the most common neurological 
disorder in equine neonates (Lyle-Dugas et al., 2016).  Hypoxic ischemic insults affect 
the central nervous system (CNS). Insufficient amounts of oxygen reach the brain and 
insufficient amounts of glucose reach the CNS system causing a cascade of changes to 
occur in order to allow neurons to react to the deficient supply of energy (Galvin and 
Collins, 2004).  Maternal predisposing factors that contribute to HIE include respiratory 
disease, endotoxemia, hemorrhage, anemia, surgery, and cesarean delivery (Galvin and 
Collins, 2004). Placental predisposing factors that contribute to HIE include placentitis, 
chronic uteroplacental separation, and acute or premature uteroplacental separation 
(Galvin and Collins, 2004). Fetal predisposing factors that contribute to HIE include 
twinning, congenital abnormalities, dystocia, aspiration of meconium, sepsis, 
prematurity, and dysmaturity (Galvin and Collins, 2004).  
 Neonates with HIE may begin to display clinical signs immediately following 
birth, however, neonates with HIE may appear normal at birth and develop clinical signs 
between 12 and 72 hours of age (Tennet-Brown et al., 2015). The most common clinical 
signs of HIE are alterations of consciousness, inability to suckle, tongue protrusion, star-
gazing, and local or generalized seizures (Lyle-Dugas et al., 2016).  While HIE is a 
disease of the CNS, other systems are typically affected including gastrointestinal tract, 
kidneys, heart, lungs, liver, adrenal glands, and parathyroid glands (Tennet-Brown et al., 
2015). 
 Diagnosing HIE is typically achieved by excluding infectious or congenital 
diseases including sepsis, hypoglycemia, prematurity, dysmaturity, bacterial meningitis, 
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hydrocephaly, epilepsy, liver disease, viral encephalitis, and toxicosis (Tennet-Brown et 
al., 2015; Lyle-Dugas et al., 2016). Laboratory results may assist in the diagnostic 
process. Often foal with HIE will have elevated creatinine levels, but does not indicate 
HIE outright (Tennet-Brown et al., 2015).  A cerebral spinal fluid analysis will rule out 
meningitis. Electroencephalography and computed tomography may be useful diagnostic 
tools in equine neonates, but it is often difficult or impractical to perform these diagnostic 
tools (Tennet-Brown et al., 2015). 
 There is no definitive treatment for HIE, but most common treatment plans for 
HIE include supportive therapy, anticonvulsive therapy, nutritional support, fluid therapy, 
antimicrobial therapy, and respiratory support (Tennet-Brown et al., 2015; Gavin and 
Collins, 2004).  Excellent nursing care and careful monitoring is crucial to the successful 
outcome of neonates with HIE (Tennet-Brown et al., 2015).  Neonates should have 
stimuli reduced and should be kept clean and dry in sternal recumbency (Gavin and 
Collins, 2004). Seizure activity can be treated with diazepam, phenobarbital, or a 
midazolam constant rate infusion (Tennet-Brown et al., 2015; Gavin and Collins, 2004).  
Neonates that are unable to stand to nurse or nurse without aspirating require enteral 
feedings via an indwelling feeding tube (Tennet-Brown et al., 2015; Gavin and Collins, 
2004). Foals that cannot tolerate enteral feedings require nutritional supplementation via 
parenteral nutrition (Tennet-Brown et al., 2015). Fluid therapy is typically used to 
optimize tissue perfusion and arterial oxygenation, however, it must be monitored 
carefully as administering too much fluid can results in an increase in cerebral edema 
(Tennet-Brown et al., 2015; Gavin and Collins, 2004). Broad-spectrum antibiotics are 
typically administered due to an increased risk of infection in neonates with HIE (Tennet-
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Brown et al., 2015; Gavin and Collins, 2004). Supplemental oxygen may be administered 
and caffeine may be administered if apnea is noticed (Gavin and Collins, 2004). The 
prognosis for neonates with HIE is good with the survival rate being at least 80% 
(Tennet-Brown et al., 2015). Neonates that recover from HIE are not expected to have 
long-term health impacts and athletic performance is not thought to be impacted (Tennet-
Brown et al., 2015). 
 
Gastrointestinal Diseases 
 There are many different gastrointestinal diseases that can affect a neonate in the 
first days of life. Two categories of equine neonatal gastrointestinal diseases are 
nondairrheal disorders and diarrheal disorders. Within diarrheal disorders there are 
infectious and non-infectious disorders. Nondiarrheal disorders of the gastrointestinal 
system in equine neonates are relatively uncommon whereas diarrheal disorders are more 
common (Ryan and Sanchez, 2005).  
 Gastric ulceration is nondiarrheal gastrointestinal disease that can cause great 
harm to a neonate. Clinical signs include inappetence or sign of colic, but are often not 
displayed until the case is severe or until rupture has occurred (Ryan and Sanchez, 2005). 
Gastric ulceration is diagnosed via gastric endoscopy (Ryan and Sanchez, 2005).  
Treatment for gastric ulceration depends on the health status of the neonate and it is 
important to consider other conditions the may coexist when determining a treatment 
plan. Histamine type 2 antagonists inhibit gastric secretions and proton pump inhibitors 
block hydrogen secretion (Ryan and Sanchez, 2005). Sucralfate is commonly 
administered; it works by adhering to ulcerated mucosa, stimulating mucus secretion, and 
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enhancing prostaglandin E and epidermal growth factor synthesis (Ryan and Sanchez, 
2005).  
 Ileus is a nondiarrheal gastrointestinal disease of equine neonates that has many 
causes, but it is commonly a secondary disease discovered in neonates with prematurity, 
sepsis, or HIE (Ryan and Sanchez, 2005). Foals with ileus typically present with gastric 
reflux or abdominal distention and typically display depressed mentation (Ryan and 
Sanchez, 2005).  Reflux and abdominal circumference should be monitored closely and 
the abdomen should be examined via ultrasound (Ryan and Sanchez, 2005).  The small 
intestine may appear fluid filled and amotile (Ryan and Sanchez, 2005). While reflux is 
present the neonate should not be fed and if large amounts of reflux are present it should 
be removed via a nasogastric tube (Ryan and Sanchez, 2005). Supportive care including 
fluid therapy and nutritional support is often necessary (Ryan and Sanchez, 2005). 
 Meconium impaction is a very common cause of colic in equine neonates (Ryan 
and Sanchez, 2005). Meconium is made of sloughed cells, swallowed amniotic fluid, and 
mucus and is formed during fetal development (Ryan and Sanchez, 2005).  Clinical signs 
of meconium impaction typically develop between 12-24 hours of age (Ryan and 
Sanchez, 2005) and include depression, abdominal distention, rolling, straining, tail-
raising, and restlessness (Ryan and Sanchez, 2005).  A diagnosis of meconium impaction 
is based on history, clinical signs, and age (Ryan and Sanchez, 2005).  Other diagnostic 
tools such as abdominal or rectal palpation or contrast radiography may assist in the 
diagnostic process (Ryan and Sanchez, 2005).  Treating meconium impaction involves 
providing fluid therapy, nutritional support, and pain management (Ryan and Sanchez, 
2005).  Soapy water enemas or retention enemas with acetylcysteine are administered to 
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break up the impaction and to encourage the meconium to pass (Ryan and Sanchez, 
2005). 
 Diarrheal gastrointestinal diseases are more common in equine neonates and can 
be infectious or noninfectious. Foals with HIE may present with diarrhea at a very young 
age due to organ dysfunction caused by tissue hypoxia (Dunkel 2008). Clinical signs 
include intolerance of feedings, meconium retention, abdominal distention, ileus, colic, 
nasogastric reflux, and watery or bloody feces (Dunkel, 2008). Diagnosing diarrhea 
caused by HIE occurs by ruling out infectious diseases and confirming the presence of 
other clinical sign associated with HIE (Dunkel, 2008).  Treatment includes fluid therapy 
as well as supplemental nutrition and feedings should be withheld or limited until 
symptoms subside (Dunkel, 2008). 
 Necrotizing enterocolitis is a life threatening disease in premature human 
neonates as well as equine neonates (Dunkel, 2008).  Due to a redistribution of cardiac 
output, ischemic injury or necrosis occurs in the intestine (Dunkel, 2008). Clinical signs 
include depression, changes in body temperature, feed intolerance, nasogastric reflux, 
ileus, hypotension, and glucose instability (Dunkel, 2008).  Treatment includes parenteral 
nutrition and treating the metabolic instabilities and sepsis (Dunkel, 2008). 
 Infectious agents are known to cause diarrheal gastrointestinal diseases in 
neonates and can be detrimental to the health of a neonate.  Common infectious agents 
that cause diarrhea in neonates are rotavirus, Salmonella spp., and Cryptosporidium 
(Dunkel, 2008). Diagnostic tools used to determine the causative agents of diarrhea in 
foals include commercially available assays, fecal cultures, PCR, and acid fast fecal 
staining (Dunkel, 2008). Treatment most often includes fluid therapy, correcting 
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electrolyte and acid-base abnormalities, antimicrobials, and nutritional support (Dunkel, 
2008).  
 
Sepsis 
 Sepsis is one of the leading causes of mortality in the equine neonate and is a 
large problem for equine practitioners because of the high mortality rate despite 
aggressive treatment (McKenzie and Furr, 2001).  Sepsis is caused by a nonspecific 
inflammatory response that occurs in response to invasion of tissue by foreign 
microorganisms (Sanchez, 2005).  There are both maternal and postnatal predisposing 
factors that can cause sepsis including dystocia, premature placental separation, maternal 
illness, placentitis, failure of passive transfer, improper umbilical care, and poor sanitary 
conditions (Sanchez, 2005).  In utero the fetus may be exposed to microorganisms that 
invade the placenta and gain access to the neonate’s bloodstream or they can infect the 
respiratory and gastrointestinal tract.  After birth, infection usually occurs through the 
umbilicus, ingestion, inhalation, or via wounds (McKenzie and Furr, 2001).  Gram-
negative bacteria are the most common cause of equine neonatal sepsis, however, mixed 
infections is common and gram-positive bacteria are often present with mixed infections 
(McKenzie and Furr, 2001).  
 Clinical signs of sepsis vary but include depression, decreased suckling, lethargy, 
and recumbency (Sanchez, 2005).  Sepsis also can result in fever, hypothermia, 
tachycardia, tachypnea, hypocapnia, leukocytosis, leukopenia, or increased number of 
immature forms of granulocytes and by definition two of these symptoms must be present 
(McKenize and Furr, 2001). Diarrhea is commonly present but other localized signs may 
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be noticed as well such as uveitis, seizures, joint effusion, lameness, respiratory distress, 
patent urachus, and omphalitis (Sanchez, 2005).  
 The blood culture is the gold standard for diagnosing sepsis (Sanchez, 2005).  
While the blood culture is useful because it identifies the causative agent, its limitations 
include that results are often delayed 48 hours and that it has poor sensitivity (Sanchez, 
2005).  A sepsis scoring system has been developed as an attempt to improve the 
diagnostic process of neonatal sepsis, but limitations still exist (McKenzie and Furr, 
2001).  
 Treatment of neonatal sepsis is complex and aggressive treatment is typically 
required for a successful outcome, however, even with aggressive treatment survival is 
not always obtainable (Sanchez, 2005). Antimicrobial therapy must be used and typically 
a broad- spectrum antibiotic is used as soon as possible (Sanchez, 2005). The 
antimicrobial therapy may be altered when the results of the blood culture are received, 
but treatment should not be withheld while waiting for the results (Sanchez, 2005). A 
recommended approach is to combine amikacin with a penicillin or ampicillin (Sanchez, 
2005). When this course of treatment is used, it is necessary to monitor the neonate’s 
creatinine levels (Sanchez, 2005).  Fluid therapy as well as nutritional support is 
necessary in most cases of sepsis (Sanchez, 2005). Current reported survival rates of 
neonates diagnosed with sepsis range from as low as 45% to as high as 72% (Sanchez, 
2005).  Performance and long-term survival of neonates with sepsis have been studied in 
limited scope (Sanchez, 2005).   
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Obtaining a differential diagnosis in the equine veterinary practice is a complex 
process that is essential to the outcome of the patient.  Correctly and efficiently acquiring 
an accurate diagnosis allows the veterinarian to determine the best-suited treatment plan 
for the patient and to obtain a prognosis for the outcome.  Most often the diagnostic 
process involves numerous blood tests run in a laboratory that provide awareness into 
what is occurring inside the horse in response to the disease process.  Some of the 
laboratory blood work routinely performed includes measuring acute phase proteins, 
which are one of the results of the inflammatory response.  Acute phase proteins give 
insight into how the body is reacting to the disease, which can show promise in 
diagnosing certain conditions.     
 
The inflammatory response 
Inflammation is the response of tissues to injury or the invasion of 
microorganisms. It plays a critical role by helping to move phagocytic cells and defensive 
molecules from the bloodstream to the affected site (McKenzie and Furr, 2001).  The 
inflammatory response begins when tissue is either injured or invaded by 
microorganisms. This initiates macrophage activation and the injured cells release 
proinflammatory enzymes and proinflammatory cytokines including interleukin-1, tumor 
necrosis factor-α, and interleukin-6 (McKenzie and Furr, 2001). One of the purposes of 
the cytokines: interleukin-1, tumor necrosis factor-α, and interleukin-6 is to initiate the 
acute phase response (McKenzie and Furr, 2001). 
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The acute phase response 
The acute phase response is a systematic chain of reactions that occur as part of 
the inflammatory response as a reaction to damage to the tissue caused by a wide variety 
of sources including bacteria, viruses, parasites, stress, and trauma (Jacobsen and 
Anderson, 2010; Satué et al., 2013). One of the outcomes of the acute phase response is 
an increase in the circulation and concentration of multiple plasma proteins referred to as 
acute phase proteins (Pepys et al., 1989).  Acute phase response proteins are 
characterized as proteins which concentrations change by at least 25% as a reaction to the 
acute phase response (Jacobsen and Anderson, 2010).  There are different classifications 
of acute phase response proteins including major, minor, positive and negative. Positive 
acute phase response proteins are proteins that increase in concentration during the acute 
phase response whereas negative acute phase response proteins decrease in concentration 
during the acute phase response. Minor acute phase proteins change in concentration by 
.5-1 times, moderate acute phase proteins change in concentration 5-10 times, and major 
acute phase proteins change in concentration 100-1000 times in response to the acute 
phase response (Jacobsen and Anderson, 2010). 
 
Serum amyloid A  
Serum amyloid A (SAA) is the only major acute phase protein identified in the 
horse (Jacobsen and Anderson, 2010).  It qualifies as a major acute phase protein because 
it exists in low or undetectable levels in the healthy horse and increases 10-1000 times in 
response to inflammatory stimulus (Jacobsen and Anderson, 2010; Satué et al., 2013).  
Serum amyloid A has been studied as an acute phase protein and indicator of infection in 
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humans and other species, but there have been a limited number of studies conducted 
evaluating applications of SAA in equine medicine (Jacobsen and Anderson, 2010, Pepys 
et al., 1989).  
Serum amyloid A is an apo-lipoprotein (Nunokawa et al., 1993) weighing 9-11 
kilodalton (Jacobsen and Anderson, 2010; Satué et al., 2013). Sletton et al. (1989) 
published the full sequence of equine SAA and three isoforms of SAA have been 
identified (Jacobsen and Anderson, 2010; Satué et al., 2013). Serum amyloid A is 
primarily synthesized by hepatocytes. However, extrahepatic synthesis of the isoform 
SAA3 has also been identified in the equine endothelial cells in the gastrointestinal tract, 
mammary glands, and airways, which may give insight into the functions of SAA 
(Jacobsen and Anderson, 2010; Satué et al., 2013). 
While SAA appears to be a particularly sensitive biomarker of infection, its exact 
functions remain unknown (Jacobsen and Anderson, 2010). Studies have shown that 
SAA performs a wide variety of functions including both influencing leucocyte function, 
impacting inflammatory mediator synthesis, assisting in lipid transportation, and 
encouraging extracellular matrix degradation by inducing enzymes (Jacobsen and 
Anderson, 2010).  
The applications of SAA in the equine clinical setting have just started to be 
explored, but numerous characteristics of the protein suggest that it has many attractive 
diagnostic properties as well as potential to be an indicator of current health status (Satué 
et al., 2013). Serum amyloid A exists in low levels in the healthy horse regardless of age, 
sex, or breed.  The normal range of SAA concentration in the horse is 0.5 mg/l to 20 mg/l 
with the majority of healthy horses having a SAA concentration under 7 mg/l (Satué et 
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al., 2013). In the presence of an inflammatory stimulus, SAA concentration begins to 
increase after 6-12 hours and peaks between 36 hours and 48 hours post stimulus 
(Jacobsen and Anderson, 2010). Serum amyloid A increases significantly and can reach 
concentrations of 3000 mg/L.  Serum amyloid A begins to decrease in concentration very 
quickly once inflammatory stimuli are removed. Serum amyloid A is degraded in the 
liver 30 minutes to 2 hours after synthesis (Satué et al., 2013).  Serum amyloid A 
concentrations reach baseline levels within 1-2 weeks with no presence of inflammatory 
stimulus (Satué et al., 2013).  
  
Serum amyloid A compared to other common markers of inflammation 
The first acute phase protein identified in humans was C-reactive protein (CRP) 
(Pepys et al., 1989). C-reactive protein exhibits many characteristics similar to SAA that 
indicates it is a good predictor of infection including a low normal concentration and 
rapid change in response to infection (Pepys et al., 1989). While CRP and SAA share 
similar characteristics, SAA increases quicker in response to inflammatory stimuli and 
increases much more drastically than CRP.  C-reactive protein only increases up to 35 
times its normal concentration and does not peak until 72-120 hours post inflammatory 
stimulus (Jacobsen and Anderson, 2010). These characteristics demonstrate why SAA 
may be a more sensitive, and, therefore, better biomarker of infection.    
One of the most commonly used acute phase proteins in the clinical setting in 
horses is fibrinogen, a minor acute phase protein. There are many characteristics of 
fibrinogen, however, that imply SAA is a better indication of infection and disease in the 
horse. Serum amyloid A exists in low levels in the healthy horse whereas fibrinogen is 
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present in high concentrations and has a wide range of normal values ranging between 
2000 and 4000 mg/l (Jacobsen and Anderson, 2010). Plasma concentrations of fibrinogen 
in inflammatory conditions range from 3000 mg/l to 11000 mg/l which is only a .5 to 5.5 
times increase compared to hundreds or a thousand time increase observed in SAA in 
inflammatory conditions (Jacobsen and Anderson, 2010).  Serum amyloid A also begins 
to increase 18-60 hours earlier than fibrinogen and peaks 24 to 96 hours sooner than 
fibrinogen in response to inflammatory stimulus (Jacobsen and Anderson, 2010).  Finally, 
where SAA clears the body quickly after the inflammatory stimuli are removed and 
resolved, fibrinogen levels remain elevated for multiple days (Jacobsen and Anderson, 
2010).  
The specific characteristics of SAA that indicate it is a more sensitive biomarker 
of infection in horse has prompted studies that compare its diagnostic capabilities to other 
commonly used biomarkers.  This research was conducted to identify SAA’s possible 
role in the equine clinic. The idea that SAA is a more sensitive indicator of inflammation 
and infection in the horse is supported by the works of Chavette et al. (1992) and Hultén 
and Demmers (2010). In those studies there was poor correlation between SAA and 
fibrinogen and white blood cell (WBC) count in foals with infectious and noninfectious 
diseases. Belgrave et al. (2013) compared SAA’s diagnostic accuracy to the diagnostic 
accuracy of total WBC count, albumin globulin ratio, and plasma fibrinogen.  Serum 
amyloid A accurately diagnosed a clinically abnormal horse 75% of the time, which was 
higher than the diagnostic accuracies of total WBC count, albumin globulin ratio and 
plasma fibrinogen, which ranged between 59% and 62%, respectively (Belgrave et al. 
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2013). In newborn foals SAA concentration was three times better at diagnosing non-
healthy foals than WBC count (Stablelab Studies).  
 
Measuring SAA  
Many different methods of measuring SAA in the horse have been evaluated 
including ELISA, single radial immunodiffusion, electroimmunoassay, latex 
agglutination immunoturbidemetric assay, and lateral flow immunoassay (Jacobsen et al. 
2006). A turbidometric immunoassay (TIA) developed for use with human serum showed 
slight, but negligible signs of inaccuracy when used to test equine serum. Jacobsen et al. 
(2006) concluded that equine SAA concentrations can be measured reliably using the 
TIA designed for human SAA. This type of test is easily automated and fast which makes 
it particularly well suited for routine diagnostic procedures and an appropriate way to 
measure SAA concentration in a veterinary laboratory (Jacobsen and Anderson, 2010). 
Commercially available point of care lateral flow immunoassay tests have been 
developed to measure SAA concentration. For ne point of care lateral flow test 
(StableLab Equine Blood Analysis Kit), the precision and accuracy have been determined 
as 98.6% and 95.6% respectively (Viner et al 2017). This lateral flow test has good 
agreement with a TIA as well (Viner et al., 2017).  Schwartz et al. (2018) found the 
correlation coefficeint for results obtained by the point of care test and the TIA to be 
0.836.  The point of care test showed acceptable linearity and precision in equine serum 
and plasma for SAA concentrations (Schwartz et al. 2018).  These types of tests are 
particularly useful where access to a laboratory is not available or where rapid results are 
desired. 
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Neonatal Disease and SAA 
As previously discussed diagnosing neonatal disease is a difficult process due to 
the nonspecific nature of the clinical signs of many neonatal diseases, and it is crucial to 
the survival of the neonate to obtain an accurate diagnosis as quickly as possible. 
Currently, diagnosing disease in equine neonates requires multiple laboratory tests, 
including a blood culture, in conjunction with a patient history and physical exam. The 
results from the laboratory results are often delayed, frequently taking 48-72 hours to 
obtain.  Serum amyloid A assays have been evaluated as a tool to diagnose disease in 
equine neonates in a limited scope.  
 Chavatte et al. (1992) compared SAA concentrations by electroimmunoassay in 
normal foals and foals with different clinical conditions including foals suffering from 
infection, foals showing signs of weakness and prematurity, and foals suffering from 
neonatal maladjustment syndrome, traumatic birth, or meconium colic. The normal foals 
had SAA concentrations that agreed with the previously established normal reference 
range of SAA concentration of 0-20 mg/l.  All foals with clinical conditions had raised 
SAA concentrations, however, the foals in the infection group had significantly higher 
SAA concentrations than the normal group and the other clinical groups. Chavatte et al. 
(1992) proposed that SAA concentrations above 200 mg/l were indicative of infection, 
SAA concentrations between 20 and 100 mg/l were indicative of a non-infective process 
associated with trauma or prematurity, and SAA concentrations below 20 mg/l were 
indicative of a normal health status.  The results of this study suggest that measuring 
SAA concentration is useful in the differential diagnosis process in regards to infection 
the neonate and foal, but SAA concentrations also rise in other conditions. 
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 In a similar study to Chavette et al. (1992), Stoneham et al. (2001) evaluated 
using a latex agglutination assay to measure SAA in the normal neonate in the first 3 days 
of life and in response to clinical diseases in the equine neonate. This study evaluated 
SAA concentration in the normal foal and in foals with septicemia, focal infection, failure 
of passive transfer of immunity, and noninfectious diseases. The results of the study 
showed that SAA concentration was increased on day 2 of life in normal foals, but the 
median SAA concentration values on days 1, 2 and 3 of life fell within previously 
established normal ranges. The median SAA concentration for the septicemia, focal 
infection, failure of passive transfer, and noninfectious disease group were 279.9 mg/l, 
195 mg/l, 5.1 mg/l and 3.1 mg/l, respectively. There was a significant difference in the 
SAA concentrations between the normal group and the septicemia group and focal 
infection group. There was also a significant difference between the septicemia group and 
the groups with failure of passive transfer and noninfectious diseases. Stoneham et al. 
(2001) concluded that measuring SAA concentration is useful in diagnosing infectious 
disease in neonates, but they suggested that a value over 100 mg/l was indicative of 
infection where as a value of 200 mg/l was suggested by Chavatte et al (1992).  
 Further research regarding using measuring SAA concentrations for diagnostic 
purposes in equine neonates supports Stoneham et al. (2001) and Chavatte et al. (1992) 
concluded that measuring SAA concentrations is useful in diagnosing infection and 
septicemia in equine neonates (Paltrinieri et al. 2008; Hultén and Demmers, 2002). 
Similar to studies evaluating SAA concentration in adults with infection, compared with 
those of other commonly used biomarkers of infection, including WBC count and 
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fibrinogen, it is suggested that SAA concentration is a more accurate indicator of 
infection in equine neonates (Hultén and Demmers, 2002; Stablelab Studies).  
 
Respiratory Diseases and SAA 
 While it is established that SAA concentration is a reliable marker of infection, its 
response to different respiratory diseases has been an area of interest. Viner et al. (2017) 
studied SAA concentration in horses with different infectious and noninfectious 
respiratory diseases, including equine influenza virus (EIV), equine herpesvirus-4 (EHV-
4), Streptococcus equi (S. equi), inflammatory airway disease (IAD), and healthy horses. 
The median SAA concentrations of the healthy, IAD, EIV, EHV-4, and S. equi groups 
were 0 mg/l, 0 mg/l, 731 mg/l, 1173 mg/l, and 1953 mg/l, respectively. There were 
significant differences in SAA concentration between horses with infectious diseases 
(EIV, EHV-4, S. equi) and the horses in the IAD group, although all horses with 
respiratory diseases were significantly different than the control group of healthy horses. 
This study concluded that SAA is more elevated in horses with infections in the 
respiratory tract when compared to those with noninfectious diseases of the respiratory 
tract. The authors of this study suggest that monitoring SAA in horses with respiratory 
diseases can assist in early detection, track disease progression, and help make decisions 
regarding biosecurity and isolation issues regarding contagious horses.  
Further studies regarding SAA concentrations in horses with respiratory diseases 
have produced similar results as Viner et al. (2017). Acute equine influenza A2 (H3N8) 
virus infection is a highly contagious virus that not only causes clinical abnormalities, but 
also predisposes them to secondary bacterial infections and causes performance to be 
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impaired. Serum amyloid A concentrations in horses with equine influenza increase 
during the first 48 hours of onset clinical signs and return to baseline values within 11-22 
days (Hultén et al., 1999). In horses with bacterial pneumonia both SAA concentrations 
and surfactant protein D (SP-D), a protein commonly used to indicate pulmonary injury, 
were elevated (Hobo et al., 2007). The increase in SAA preceded the increase in SP-D, 
which increased with the presence of clinical signs suggesting that measuring SAA 
concentrations could help identify bacterial pneumonia before clinical signs are present 
(Hobo et al., 2007). Elevated SAA concentration was also detected in horses with heaves 
compared to healthy horses (Lavoie-Lamoureux et al., 2012).  
One area of particular interest regarding SAA concentration and respiratory 
diseases has been regarding using SAA concentration to detect and monitor Rhodococcus 
equi pneumonia in foals. Passamonti et al. (2015) and Cohen et al. (2010) both evaluated 
the usefulness of monitoring SAA concentration as a means of early detection for R. equi 
pneumonia. This is of particular interest due to the subtle clinical signs presented in the 
early stages of R. equi pneumonia. The results of both studies showed that SAA 
concentrations in foals with R. equi pneumonia were varied and therefore it is suggested 
that SAA concentration is not a helpful tool in the early diagnosis process of R. equi 
pneumonia in foals. While measuring SAA concentration is not useful in early detection, 
it may be useful in determining real time health status and effectiveness of therapy.  
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Surgery and SAA 
The effects of surgery on SAA concentration have been examined in several 
different contexts. Surgery induces the acute phase response and therefore prompts a rise 
in SAA concentration (Jacobsen et al., 2010).  It is suggested, however, that general 
anesthesia alone does not cause an increase in SAA concentration (Pepys et al., 1989).  In 
most cases SAA concentration is elevated 24 hours post surgery and remains elevated for 
a short period of time before returning to normal levels.  There is variation in the degree 
of the increase as well as the longevity of the increased concentration, but a SAA 
concentration that remains elevated may suggest post-surgical complications such as 
infection (Jacobsen et al., 2010). 
Pollock et al. 2005 evaluated SAA concentration in horses after elective surgery 
and non-elective surgery compared to normal horses and found that both groups of horses 
who had surgery had significantly higher mean SAA concentrations compared to the 
control group of healthy horses 24 hours after the surgery.  
Jacobsen et al. 2010 found that horses had elevated SAA concentrations 3 days 
post castration. In cases that had mild inflammation and uncomplicated surgery, SAA 
concentrations returned to normal levels 8 days post surgery. In cases that had moderate 
to severe inflammation post surgery, SAA concentration remained elevated throughout 
the course of the study.  The results of this study suggested that fever and leucocyte count 
were not useful tools when monitoring post castration surgery and SAA may improve 
post operative monitoring because its concentration revealed the level of inflammation 
present and correlated with the level of clinical severity of the inflammation.  
	
	
	
	 	
	
23	
Pepys et al. 1989 saw increased SAA concentrations post surgery for horses that 
underwent exteriorization of the carotid artery and division of flexor tendons that peaked 
2-3 days and returned to normal values within 7-14 days post surgery.  
Monitoring SAA concentration may be useful in post surgery management. 
Serum amyloid A concentrations that remain elevated for prolonged periods of time post 
surgery may indicate infection or a complication from the surgery process or a delay in 
the healing process.  Measuring SAA concentration as a management tool may provide 
insight into the health status of the individual post surgery and indicate when the healing 
process is complete.  
 
Conclusion 
 Serum amyloid A is an acute phase protein that has potential to be a useful 
indicator of infection and disease in the equine clinic.  Because it increases in response to 
the initiation of the acute phase response, its use as a differential diagnostic tool may be 
somewhat limited as it increases in response to infection and not to a specific disease 
process.  The ability of SAA to rise significantly and quickly in response to inflammatory 
stimuli makes it a particularly valuable diagnostic tool that can aid in early detection of 
infection as well as current health status and response to treatment. While research 
regarding the applications of SAA in the equine clinical setting is limited to date, it is 
apparent that SAA has usefulness as a diagnostic tool.  The development of a point of 
care test able to measure SAA concentrations without access to a laboratory may be 
particularly useful to some veterinarians in remote areas. 
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Chapter Two: Introduction 
 
Rationale 
 
 The current diagnostic process for diagnosing disease in the equine neonate is a 
complex process that combines knowledge of patient history and physical examination 
and diagnostic tests including extensive laboratory blood work. While this information 
provides the veterinarian with a comprehensive overview of the patient, the diagnostic 
process is often slowed by delayed results of the laboratory blood work.  Also, 
veterinarians in remote areas may experience significant delays in laboratory results due 
to limited access to a lab. Obtaining an accurate diagnosis in a rapid time frame greatly 
improves the neonate’s chance of survival because many neonatal diseases progress 
quickly and foal succumb to rapid deterioration. Identifying a biomarker of disease that 
can be quantified early in the disease process and easily obtained by a veterinarian, would 
improve diagnostic procedures by allowing the veterinarian to receive valuable 
information within a critical time frame.  Because it is a sensitive acute phase protein and 
there is a point of care test kit available, serum amyloid A has been suggested as a 
possible biomarker of disease in equine neonates. The studies presented in this thesis 
whether serum amyloid A can serve as a biomarker of disease in equine neonates in order 
to remedy a large problem that exists in the equine veterinary practice.  
 
Hypotheses and Objectives 
 
 Hypothesis 3.1: A SAA concentration above 100 mg/l is associated with equine 
neonatal sepsis  
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 Objective 3.1: To assess measuring serum amyloid A (SAA) using a 
commercially available point of care lateral flow kit to diagnose sepsis in neonates less 
than one week of age.  
Hypothesis 4.1: Median SAA concentrations will differ between diagnostic 
groups 
Hypothesis 4.2: A SAA value greater than 100 mg/l is indicative of disease 
Hypothesis 4.3: The optimum age to test SAA concentration is over 12 hours of 
age in order to allow for the SAA concentration to accumulate in response to a disease. 
Objective 4.1: To assess measuring SAA using a point of care test to diagnose 
disease in the equine neonate 
Objective 4.2: To identify differences in SAA concentration between diagnoses 
Objective 4.3: To identify changes in SAA concentration over the course of 72 
hours post admission 
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Chapter Three 
 
Assessing the use of a commercially available point of care serum amyloid A test for 
diagnosing sepsis in equine neonates 
 
 
Abstract 
Objective - To assess measuring serum amyloid A (SAA) using a commercially available 
point of care lateral flow kit to diagnose sepsis in equine neonates less than one week of 
age.   
Design – Retrospective case series of equine neonates from one equine hospital between 
the years 2014-2016.  
Animals – 126 neonates under one week of age grouped based on primary diagnosis 
(colitis, contracted limbs, enteritis, hypoxic-ischemic encephalopathy (HIE), pneumonia, 
premature birth, sepsis, weak foal and normal).  
Procedures – Peripheral blood was obtained from each neonate by jugular catheter upon 
admission or immediately after birth at the hospital. The blood serum was tested using 
the StableLab Equine Blood Analysis Kit. The data were analyzed using the Wilcoxon 
rank sum test in SAS.  
Results - The median SAA concentration varied by diagnostic group. There was a 
significant difference between the SAA concentrations for the colitis, premature birth, 
contracted limbs, weak foal, HIE and normal foal groups when compared to the sepsis 
group. There was no significant difference between the SAA concentrations for the 
enteritis or pneumonia groups when compared to the sepsis group.  
Discussion and Clinical Relevance - The results of this study suggest that a 
commercially available point of care lateral flow kit is a helpful tool in diagnosing sepsis 
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in neonates less than one week of age because it allows for rapid results and does not 
require access to a laboratory. While additional testing is needed to differentiate between 
infectious diseases, the test can provide veterinarians with valuable diagnostic 
information within a critical time frame.  
 
Introduction 
 Equine neonatal sepsis has been identified as one of the major causes of mortality in 
the young foal (Sanchez, 2005). Sepsis is a nonspecific inflammatory response initiated 
by the presence of foreign microorganisms in sterile tissue (Sanchez, 2005). The disease 
manifests itself in a variety of ways, including fever, tachycardia, tachypnea, and 
leukocytosis/leukopenia (McKenzie and Furr, 2001). The systemic nature of the disease 
allows for rapid progression and quick deterioration of the body, which must be 
combated by early diagnosis and aggressive treatment for a successful outcome 
McKenzie and Furr, 2001).  
 Due to the non-specific manifestations of the disease, it can be difficult for 
practitioners to diagnose equine neonatal sepsis (Palmer, 2014). Currently the gold 
standard for the definitive diagnosis of sepsis in equine neonates is the blood culture test, 
which allows the causative agent to be identified (Sanchez, 2005). The disadvantages of 
the blood culture are that results are delayed, and that it has poor sensitivity and will only 
detect bacterial infection (Sanchez, 2005; Palmer, 2014). In 1988 Brewer and Koterba 
developed a sepsis scoring system to be used to identify sepsis in hospitalized equine 
neonates by weighting laboratory results, patient history information, and a physical 
examination parameters (Palmer, 2014). While the scoring system is a useful tool, it still 
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possesses limitations that leave a need for the identification of a practical biomarker of 
disease (Palmer, 2014). Limitations of the sepsis scoring system include requiring 
multiple blood tests as well as access to a laboratory, which can often cause a delay in the 
initiation of treatment.  
 Finding a marker of infection that is sensitive enough to detect infection, specific 
enough to discriminate between infections and other stimuli, and easily measured early in 
the course of disease would be a significant advancement in diagnosing equine neonatal 
sepsis (Palmer, 2014). Serum amyloid A is an apolipoprotein that plays a role in host 
defense mechanisms and provides local protection against invading microorganisms 
(Jacobsen and Anderson, 2010). SAA is the only major acute phase protein identified in 
the horse (Belgrave et al., 2013).  The low or nonexistent normal levels, significant and 
quick increase in response to stimuli, and short half-life of SAA in equines makes it an 
attractive biomarker for equine neonatal sepsis (Jacobsen and Anderson, 2010; Belgrave 
et al., 2013; Satué et al., 2013).   
 The objective of this study was to evaluate the ability of SAA concentration to serve 
as a biomarker for bacterial sepsis using a commercially available stall-side lateral flow 
kit in neonates less than one week of age.  The working hypothesis was that a SAA 
concentration above 100 mg/l is associated with equine neonatal sepsis.  
 
Materials and methods 
 The clinical records of neonates admitted to, or born at, the Rood and Riddle Equine 
Hospital in Lexington, Kentucky between the years of 2014-2016 were examined 
retrospectively. A neonate was defined as a foal less than 7 days old.  Records from 
	
	
	
	 	
	
29	
neonates that were tested for SAA were used in the study.  Of the 278 foals admitted to 
the neonatal intensive care unit during the study period, 167 were tested for SAA based 
on clinician discretion.  Thirty-one of these foals were eliminated from the study due to 
being over seven days of age. Of the 136 neonates 7 days of age and under who were 
tested for SAA, 10 foals were excluded from the study due to incomplete medical 
records. The clinical records of 126 neonates were included in the analysis and grouped 
into 9 categories based on primary diagnosis: colitis, contracted limbs, enteritis, hypoxic-
ischemic encephalopathy (HIE), pneumonia, premature birth, sepsis, weak foal and 
normal. One of the three attending veterinarians determined primary diagnosis after 
obtaining the patient’s history, completing a physical examination, interpreting blood test 
results and performing other diagnostics such as ultrasound or radiographs. The 
characteristics of each diagnostic group that must be present in order for the attending 
veterinarian to determine a primary diagnosis are presented in Table 3.1.  
 Blood was obtained from each neonate by jugular venipuncture or a jugular catheter 
upon admission, or immediately after, birth at the hospital. Each sample was immediately 
placed into vacutainer blood collection tube with no additive and allowed to clot. The 
serum from the samples was separated via centrifugation at 2500 RPM for 5 minutes.  All 
serum samples were analyzed for SAA concentration the same day they were collected 
using a commercially available point of care lateral flow immunoassay test that 
determines SAA concentration (Stablelab SAA test, Sligo, Ireland). According to the 
manufacturer of the kit the precision and accuracy of the test are 98.6% and 95.6% 
respectively (Viner et al., 2017). The test has shown good linearity and agreement with a 
TIA (Viner et al., 2017).  
	
	
	
	 	
	
30	
 The distribution of data for SAA concentration was tested for normality using the 
Shapiro-Wilks test. The data had a nonnormal distribution so median values were used 
and the Wilcoxon rank sum test was used to determine significant differences of SAA 
concentrations between the sepsis and other diagnostic groups and the normal and other 
diagnostic groups.  The statistical analysis was performed using a statistical software 
(PROC NPAR1WAY, SAS, version 9.3, SAS Institute Inc., Cary, NC). P-values less than 
< 0.05 were deemed significant. 
Results  
 The median SAA concentrations for the normal, contracted, premature, weak foal, 
and HIE were within the normal range for neonates of 0-20mg/l, which was determined 
by the manufacturer (0, 7, 5, 0, and 6 mg/l, respectively) (Table 3.2) (Di-Sien Chan, 
Stablelab, Sligo, Ireland).  The median SAA concentration for the colitis group was 65 
mg/l, which indicated possible infection (Table 2) (Di-Sien Chan, Stablelab, Sligo, 
Ireland).  The median SAA concentrations for the enteritis, pneumonia, and sepsis were 
above 100 mg/l (390, 1834, and 510 mg/l respectively), which was indicative of infection 
(Table 2) (Di-Sien Chan, Stablelab, Sligo, Ireland).  The ranges of SAA concentrations 
by diagnostic group are presented in Table 3.2.  
 There were significant differences in SAA concentration between the sepsis 
compared to the colitis (p = 0.0151), contracted (p=0.0052), HIE (p=0.0007), normal 
(p=0.0001), premature (p=0.0009), and weak foal (p<0.0001) groups (Table 3.2). There 
was no significant difference between the sepsis group and enteritis and pneumonia 
groups (Table 3.2). There was a significant difference in SAA concentration between the 
normal group compared to the sepsis, pneumonia, and enteritis groups (Table 3.2). There 
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was no significant difference between the normal group and the colitis, contracted, HIE, 
normal, premature, and weak foal groups (Table 3.2). 
Discussion  
 It is difficult to obtain a diagnosis for equine neonates because clinical signs vary 
from case to case and are often not specific to one differential diagnosis. While 
monitoring SAA levels is shown to be a helpful tool in diagnosing sepsis in equine 
neonates, it should be used in conjunction with other diagnostic tools and should not be 
used as the sole criteria for diagnosis (Sanchez, 2005; Palmer, 2014). In this study SAA 
values were significantly different than the normal group for multiple diagnostic groups 
including the sepsis, pneumonia and enteritis groups. To differentiate between each of 
these diagnosis, further testing and clinical observation is required. Decreasing the time 
between onset of disease and initiation of treatment is essential to achieving a successful 
outcome of disease. Even though further testing is necessary to obtain a diffinitive 
differential diagnosis, observing an SAA value above 100 mg/l provides a veterinarian 
with enough information to initiate treatment, which most often includes antibiotics and 
supportive care.   
 Because SAA is the only identified major acute phase protein in the horse it possesses 
qualities that make it a more useful diagnositc tool than commonly used proteins such as 
fibrinogen, which is a minor acute phase protein. Serum amyloid A exists in the healthy 
horse in a low and narrow range of concentrations (0-20 mg/l) in comparison to 
fibrinogen, which has a normal value between 2000-4000 mg/l (Jacobsen and Anderson, 
2010). Serum amyloid A increases up to 1000 times in response to inflammatory stimuli 
whereas fibrinogen only increases up to 10 times its normal value (Jacobsen and 
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Anderson, 2010).  Serum amyloid A begins to increase just 6 hours post inflammatory 
stimuli and peaks just 48 hours post stimuli (Jacobsen and Anderson, 2010). Fibrinogen 
levels do not begin to increase until 24 hours post inflammatory stimuli and does not 
reach peak values until up to 144 hours post stimuli (Jacobsen and Anderson, 2010).  
 A limitation of this study was that single samples were used, rather than serial 
samples.  Because SAA begins to increase 6 hours post inflammatory stimuli, the SAA 
values obtained in this study may reflect rising values as opposed to peak values.  The 
range for each diagnostic group had a minimum of 0 mg/l with the exception of the 
pneumonia group which had a minimum value of 3 mg/l.  This was a result of testing 
foals that were 0 hours of age. At this time point, SAA had not had a chance to increase 
in circulation. Collecting serial samples would decrease the risk of obtaining false 
negatives and, therefore, incorrectly declaring a neonate free of infection because the 
value has not reached its peak. Serial testing of SAA values over time may also provide 
insight into efficacy of treatment and convalescence of disease. Additionally, obtaining 
serial samples may help determine the optimum time to test SAA concentration in order 
to detect sepsis. Further studies in this area are necessary to evaluate the importance of 
serial SAA samples in diagnosing sepsis and disease in the equine neonate.  
 Serum amyloid A values in this study were determined using a commercially 
available stall side test. This type of test eliminates the time period between the initial 
examination by the veterinarian and initiation of treatment that exists when laboratory 
tests are used.  A stall side SAA kit allows an ambulatory veterinarian to perform an 
initial examination and initiate treatment within minutes of each other, which may 
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eliminate an additional visit to the patient.  This type of test would be especially useful in 
remote areas or in locations that do not have access to a laboratory.  
 The specific age range (foals less than one week of age) and large number of cases in 
this study make the study population unique compared to other studies evaluating using 
SAA to diagnose disease in foals. One of the first studies in this area suggested that SAA 
concentrations over 200 mg/l is associated with infection and that SAA concentrations 
between 20-100 indicate a non-infective process (Chavatte et al., 1992), however, a more 
recent study suggested that a value over 100 mg/l is indicative of infection (Stoneham et 
al, 2001).  Stoneham et al. (2001) concluded that the measurement of SAA concentrations 
is a useful tool in diagnosing infection in young foals; the results of the present study also 
support measuring SAA concentrations for diagnosing infection in equine neonates less 
than one week of age. 
 In conclusion, the results of this study indicate that measuring SAA concentrations 
using a commercially available stall side test is helpful in diagnosing equine neonatal 
sepsis, enteritis, and pneumonia.  The results support that a SAA concentration greater 
than 100 mg/l is associated with equine neonatal sepsis; however, a SAA concentration 
greater than 100 mg/l does not specifically indicate sepsis. Further diagnostic evaluation 
is required to differentiate between infectious diseases, including pneumonia, sepsis, and 
enteritis.  
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Table 3.1: Characteristics required to be present to obtain primary 
diagnosis 
 
Primary Diagnosis n Required characteristics used for 
veterinarian to determine primary 
diagnosis 
Colitis 9 Diarrhea, abdominal 
discomfort/distention 
Contracted Limbs 6 Difficulty standing, abnormal position 
of limb/joint 
Enteritis 11 Abdominal discomfort, nasogastric 
reflux, immobile/dilated small 
intestine on ultrasound 
HIE 16 Neurologic signs not caused by 
infection 
Pneumonia 10 Abnormal lung auscultation, 
consolidation/abscesses on ultrasound 
Premature Birth 9 Gestational length, low birth weight, 
domed forehead, short hair coat, 
periarticular laxity, floppy ears, weak 
suckle, small frame, generalized 
weakness 
Sepsis 18 Positive blood culture 
Weak Foal 33 Slow to stand/nurse, normal 
thorax/abdomen ultrasound 
Normal 13 Normal blood work and physical exam  
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Table 3.2: SAA concentration data by primary diagnosis  
Primary 
Diagnosis 
No. of foals Median mg/l Range mg/l P-value 
Normal* 13 0 0-215 0.0001 
Colitis* 9 65 0-1470 0.0151 
Contracted* 7 7 0-538 0.0052 
Enteritis^ 11 390 0-2640 0.1375 
HIE* 16 6 0-953 0.0007 
Pneumonia^ 10 1834 3-4724 0.2776 
Premature* 9 0 0-46 0.0009 
Sepsis^ 18 510 0-4764  
Weak Foal* 33 5 0-1106 <0.0001 
* Significantly different from sepsis group (P<0.05) 
^ Significantly different from normal group (P<0.05) 
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Figure 3.1: SAA concentration min, Q1, median, Q3, max by primary diagnosis 
 
Figure 3.1: Min, Q1, median, Q3, and max SAA concentration for colitis, 
contracted, enteritis, HIE, normal, pneumonia, premature, sepsis and weak foal 
diagnostic groups.  
* Significantly different from sepsis group (P<0.05) 
^ Significantly different from normal group (P<0.05) 
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Chapter Four 
 
Time series analysis of serum amyloid A concentration in hospitalized equine 
neonates 
 
Abstract  
Objective - To assess measuring SAA using a stall side test to diagnose disease in the 
equine neonate, to identify differences in SAA concentration between diagnoses, and to 
identify differences in SAA concentration at different time points 
Design – Time series analysis of equine neonates from one equine hospital between the 
January 2017 and July 2017.  
Animals – 24 neonates under 48 hours of age at admission with primary diagnoses of 
pneumonia, gastrointestinal disease and hypoxic-ischemic encephalopathy (HIE).  
Procedures – Peripheral blood was obtained from each neonate by jugular catheter 0, 12, 
24, 48, and 72 hours post admission. Serum was tested using the StableLab Equine Blood 
SAA Analysis Kit. Statistical analysis was performed using SAS PROC GLIMMIX. P-
values less than 0.05 were deemed significant.  
Results - There were significant differences in median SAA concentration between the 
encephalopathy group and the pneumonia group (p=0.0025) and the encephalopathy 
group and the gastrointestinal group (p=0.0002) over the course of the study.  There was 
no significant difference in SAA concentration between the pneumonia and 
gastrointestinal groups. 
 Discussion and Clinical Relevance - The results of this study suggest that a 
commercially available point of care lateral flow kit is a helpful tool in diagnosing 
disease in neonates when tested after 12 hours of age because it allows for rapid results 
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and does not require access to a laboratory. While additional testing is needed to 
differentiate between diseases, the test can provide veterinarians with valuable diagnostic 
information within a critical time frame.  
Introduction 
Diagnosing equine neonatal diseases is a difficult process due to the nonspecific 
or subclinical manifestations of many common neonatal diseases (Chavatte et al. 1992; 
Hultén and Demmers, 2002; Jacobsen and Anderson, 2010; Stoneham et al., 2001).  
Diagnostic testing is often extensive and includes multiple laboratory tests. This is not an 
ideal practice because it is important to minimize the amount of blood obtained from a 
neonate and because laboratory test results may take hours to days to obtain, thus 
delaying the initiation of treatment (Paltrinieri et al.; 2008). Compromised neonates have 
a high risk of rapid deterioration and therefore a quick and accurate diagnosis is essential 
in order to obtain a successful outcome for the individual (Hultén and Demmers, 2002; 
Stoneham et al., 2001). Utilizing a biomarker of disease that is sensitive enough to detect 
infection at an early stage of disease would greatly improve the diagnostic process and 
would result in an improved prognosis (Stoneham et al., 2001). 
Serum amyloid A (SAA) is the only major acute phase response protein identified 
in the equine. Serum amyloid A has been studied extensively in humans, but its research 
in the horses is limited (Jacobsen and Anderson, 2010). While the exact functions of SAA 
in the horse are unknown, it has several purposes in the inflammatory response.  These 
include enhancing and inhibiting leukocyte functions, inducing enzymes involved in the 
degradation process, affecting lipid transportation, and influencing inflammatory 
mediator synthesis (Jacobsen and Anderson, 2010). Serum amyloid A is a more sensitive 
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acute phase protein than other commonly used biomarkers (Satué et al., 2013). It exists in 
low or nonexistent levels in the healthy horse and responds significantly and quickly in 
response to inflammatory stimulus. Serum amyloid A concentrations begin to rise 6-8 
hours post inflammatory stimulus and peak at 36-48 hours post stimulus (Satué et al., 
2013). In comparison, fibrinogen begins to increase 24-72 hours post inflammatory 
stimulus and peaks between 72-144 hours post inflammatory stimulus (Jacobsen and 
Anderson, 2010). Being able to detect a noticeable difference in SAA concentration 
within the first 24 hours of life, compared to the first few days of life, allows treatment to 
be started sooner and increases the chance of survival for the neonate.  
The objectives of this study were to assess measuring SAA using a point of care 
test to diagnose disease in the equine neonate, to identify differences in SAA 
concentration between diagnoses, and to identify changes in SAA concentration over the 
course of 72 hours post admission. The working hypotheses of the study were that 
median SAA concentrations will differ between diagnostic groups, a SAA value greater 
than 100 mg/l is indicative of disease, and that the optimum age to test SAA 
concentration is over 12 hours of age in order to allow for the SAA concentration to 
accumulate in response to a disease.  
Materials and Methods 
This study was a time series analysis that was comprised of 24 neonates between 
0 and 48 hours of age at admission.  The neonates included in this study were admitted to 
Rood and Riddle Equine Hospital between February 2017 and June 2017.  Inclusion 
criteria for the study consisted of being between 0 and 48 hours of age at admission and 
having blood samples collected at each time point of the study. The foals were grouped 
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into three primary diagnoses: pneumonia (n=8), HIE (n=8), and gastrointestinal disease 
(n=8). One of the three attending veterinarians determined primary diagnosis after 
obtaining the patient’s history, completing a physical examination, interpreting blood test 
results and performing other diagnostics such as ultrasound or radiographs. The specific 
characteristics required to diagnose pneumonia, HIE, and gastrointestinal disease are 
presented in Table 4.1.  
Blood was obtained from each foal via jugular catheter at 0, 12, 24, 48 and 72 
hours post admission. The blood was stored in a 5ml vacutainer with no additive and 
allowed to clot. The serum was separated via centrifugation at 2500 RPM for 5 minutes 
and stored in a freezer at -30° C.  After thawing the serum and allowing it to reach room 
temperature, the serum was tested for SAA concentration using a commercially available 
point of care lateral flow kit (Stablelab SAA test, Sligo, Ireland). For the purpose of this 
study a SAA concentration greater than 100 mg/l was considered indicative of infectious 
disease.   
 Because the data had a non-Gaussian distribution median values were reported. The 
statistical analysis was performed using statistical software (SAS, version 9.3, SAS 
Institute Inc., Cary, NC).  Differences in SAA concentration between primary diagnoses 
were determined by using Tukey grouping of the least square means to adjust for multiple 
comparisons.  PROC GLIMMIX was used to obtain differences in SAA concentration 
between primary diagnoses. PROC GLIMMIX estimates trends in disease rates, 
modeling proportions over time in a clinical trial, and predicts the probability of 
occurrence in times series. P-values less than 0.05 were deemed significant. 
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Results  
 
The median SAA concentrations for all neonates in this study at 0, 12, 24, 48, and 
72 hours post admission were 32.5 mg/l, 566 mg/l, 712 mg/l, 466 mg/l, and 161.5 mg/l  
respectively (Fig 4.1). The range of SAA concentrations for all neonates in this study at 
0, 12, 24, 48, and 72 hours post admission were 0-3000 mg/l, 26-2784 mg/l, 33-2777 
mg/l, 11-2679 mg/l, and 0-2234 mg/l respectively (Fig 4.1). The median SAA 
concentrations for the pneumonia and encephalopathy groups at admission were under 
100 mg/l (41 mg/l and 2 mg/l respectively) whereas the median SAA concentration at 
admission for the gastrointestinal foals was greater than 100 mg/l (463 mg/l) (Fig 4.2). 
The median SAA concentration was above 100 mg/l for all three diagnostic groups at the 
12, 24, and 48-hour post admission. All three diagnostic groups had increasing median 
SAA concentrations during the 0, 12 and 24-hour post admission time samples with the 
greatest increase occurring between the 0 and 12 hour time samples. The median SAA 
concentration for the encephalopathy group at the 72-hour post admission time sample 
was below 100 mg/l (55 mg/l), while the median SAA concentration at 72-hour post 
admission for the pneumonia and gastrointestinal groups remained elevated at 581 mg/l 
and 266 mg/l respectively. The ranges of SAA concentration for the pneumonia group at 
0,12, 24, 48, and 72 hours post admission were 6-84 mg/l, 162-2673 mg/l, 136-2432 
mg/l. 41-2679 mg/l and 0-2234 mg/l respectively.  The ranges of SAA concentration for 
the gastrointestinal group at 0, 12, 24, 48, and 72 hours post admission were 0-3000 mg/l, 
450-2784 mg/l, 448-2528 mg/l, 159-2345 mg/l, and 12-2206 mg/l respectively. The 
ranges of SAA concentration for the HIE group at 0, 12, 24, 48, and 72 hours post 
admission were 0-53 mg/l, 26-420 mg/l, 33-735 mg/l, 11-476 mg/l, ad 0-317 mg/l 
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respectively. The median SAA concentrations and ranges of SAA concentration for each 
diagnostic at each time point are presented in Figures 4.2-4.6.  
There were significant differences in median SAA concentration between the 
encephalopathy group and the pneumonia group (p=0.0025) and the encephalopathy 
group and the gastrointestinal group (p=0.0002) over the course of the study (Table 4.2).  
There was no significant difference in SAA concentration between the pneumonia and 
gastrointestinal groups. 
At 0 hours post admission 100% of the neonates in the pneumonia group, 25% 
neonates in the gastrointestinal group, and 100% of the neonates in the encephalopathy 
group had SAA values below 100 mg/l. At 12 hours post admission 0% of the neonates in 
the pneumonia group, 0% of the neonates in the gastrointestinal group, and 25% of the 
neonates in the encephalopathy group had SAA values below 100 mg/l. At 24 hours post 
admission 0% of the neonates in the pneumonia group, 0% of the neonates in the  
gastrointestinal group, and 37.5% of the neonates in the encephalopathy group had SAA 
values below 100 mg/l. At 48 hours post admission 12.5% of the neonates in the 
pneumonia group, 0% of the neonates in the gastrointestinal group, and 37.5% of the 
neonates in the encephalopathy group had SAA values below 100 mg/l. At 48 hours post 
admission 12.5% of the neonates in the pneumonia group, 37.5% of the neonates in the 
gastrointestinal group, and 62.5% of the neonates in the encephalopathy group had SAA 
values below 100 mg/l. These values are displayed in Figure 4.7.  
 
Discussion 
 
 The differential diagnostic procedure in neonates is a complicated process that 
poses many challenges for the equine industry. It is important to note that no single 
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diagnostic test should be used to differentially diagnose a neonate in the clinical setting 
(Chavatte et al., 1992).  For the most accurate diagnosis, a combination of diagnostic 
procedures should be considered.  
The median SAA concentrations, regardless of diagnostic groups, were above 100 
mg/l at all time points except for at 0 hours post admission.  This corresponded to 0 hours  
of age for all but 6 foals in the study.  At 12 hours post admission, however, all foals in 
the pneumonia and gastrointestinal groups had SAA concentrations above 100 mg/l. 
These results suggest that testing for SAA concentration at 0 hours of age would not be 
beneficial to the diagnostic process. SAA concentrations do not begin to increase until 6-
8 hours post inflammatory stimulus, thus it is more worthwhile to test SAA concentration 
after it has had sufficient time to accumulate. The authors of this study recommend 
assaying SAA concentration no earlier than 12 hours of age to detect elevated levels 
associated with disease. 
 While the encephalopathy group had a significantly lower SAA concentration 
than the pneumonia and gastrointestinal groups, it did have median SAA concentrations 
over 100 mg/l.  This is likely because SAA increases in response to other conditions 
besides infection, including trauma and stress (Belgrave et al., 2013). Continued testing 
for SAA should be used for these cases to monitor for decreasing or slightly increasing 
SAA concentrations.  Neonates with encephalopathy are compromised and have a larger 
susceptibility to infection compared to a healthy neonate (McKenzie and Furr, 2001). 
 The results of this study did show a significant difference in the SAA 
concentrations of the pneumonia group and the encephalopathy group and the 
gastrointestinal group and the encephalopathy group.  These results support that the SAA 
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test can be a useful tool in diagnosing disease in neonates. This finding agrees with 
previous authors’ conclusions as well (Chavatte et al., 1992; Stoneham et al., 2001). A 
SAA concentration above 100 mg/l should be recognized as a possible indication of 
disease or infection, and further diagnostic testing should be pursued. Follow-up SAA 
testing should be performed in order to follow the current health status of the patient.  
 A point of care test that is able to quantify SAA concentration within minutes is 
especially useful for veterinarians in remote locations without access to a laboratory.  A 
low SAA concentration obtained from a foal less than 12 hours of age, indicates a healthy 
foal that may not need further testing and does not require treatment such as antibiotics. 
A high SAA concentration indicates need for further testing and alerts veterinarians that 
the foal will require further testing and treatment to some extent.  
One limitation of this study is that the average age of the gastrointestinal group 
was higher than the other two diagnostic groups. This could explain the higher median 
SAA concentration at 0 hours post admission for this diagnostic group. Ideally, all foals 
included should have been the same age at admission. A second limitation of this study is 
that there was no normal neonate group to compare to the clinically abnormal cases. 
Accumulating this data would give insight to patterns of SAA concentration over time in 
clinically normal foals and allow us to compare this data to clinically abnormal foals; 
however, data regarding SAA concentrations in healthy foals has been obtained and 
analyzed in previous works including the study in chapter 3 of this thesis.  Finally, the 
neonates in this study were grouped based on primary diagnosis, but other diseases are 
often present. This could explain elevated SAA in the encephalopathy group because, 
even though pneumonia or a gastrointestinal disease was not the neonate’s primary 
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diagnosis, it is possible that the neonate subsequently presented with symptoms of these 
diseases as well.  
 Given the limited number of studies regarding SAA concentration in the equine, 
and especially in the equine neonate, equine clinicians are determining where the SAA 
test best fits into their wide variety of tools. This study does support that a point of care 
test for SAA is useful in the diagnostic process for equine neonates and is especially 
helpful for veterinarians without access to a laboratory.  Obtaining a SAA concentration 
provides a veterinarian with a good starting point and can help the veterinarian determine 
what the next step should be. It would be beneficial for future studies in this area to 
evaluate using SAA as a tool to determine efficacy of treatment and convalescence of 
disease.  
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Table 4.1: Characteristics used to obtain primary diagnosis 
 N Primary 
Diagnosis 
Required characteristics used for 
veterinarian to determine primary 
diagnosis 
 
 8 Gastrointestinal 
Disease* 
Abdominal discomfort/distention, nasogastric reflux, 
immobile/dilated small intestine on ultrasound, diarrhea 
 8 HIE Neurologic signs not caused by 
infection 
        
 8 Pneumonia Abnormal lung auscultation, 
consolidation/abscesses on ultrasound 
    
      * Not all characteristics must be 
present to obtain this diagnosis 
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Table 4.2: Median SAA concentrations for each primary diagnosis at different time 
points post admission 
      Median SAA Concentration, mg/l 
Diagnostic 
Group 
n Median Age 
(hrs) 
0 Hrs 12 Hrs 24 Hrs 48 Hrs 72 
Hrs 
PneumoniaA 8 0 41 677 843 1076 581 
GastrointestinalA 8 24 463 951 1201 455 266 
EncephalopathyB 8 0 2 273 489 144 56 
Diagnostic groups denoted with the same letter were not significantly different from each other 
Diagnostic groups denoted with different letters were significantly different from each other 
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Figure 4.1: Min, Q1, medians, Q3, and max SAA concentrations of all neonates 
(n=24) at 0, 12, 24, 48, and 72 hours post admission.  
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Figure 4.2: Min, Q1, median, Q3, and max SAA Concentration for pneumonia 
(n=8), gastrointestinal (n=8) and encephalopathy (n=8) diagnostic groups at 0 hours 
post admission  
 
 
Figure 4.3: Min, Q1, median, Q3, and max SAA Concentration for pneumonia 
(n=8), gastrointestinal (n=8) and encephalopathy (n=8) diagnostic groups at 12 
hours post admission  
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Figure 4.4: Min, Q1, median, Q3, and max SAA Concentration for pneumonia 
(n=8), gastrointestinal (n=8) and encephalopathy (n=8) diagnostic groups at 24 
hours post admission  
 
Figure 4.5: Min, Q1, median, Q3, and max SAA Concentration for pneumonia 
(n=8), gastrointestinal (n=8) and encephalopathy (n=8) diagnostic groups at 48 
hours post admission  
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Figure 4.6: Min, Q1, median, Q3, and max SAA Concentration for pneumonia 
(n=8), gastrointestinal (n=8) and encephalopathy (n=8) diagnostic groups at 72 
hours post admission  
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Figure 4.7: Percent of cases in pneumonia (n=8), gastrointestinal (n=8), and 
encephalopathy (n=8) diagnostic groups at 0, 12, 24, 48, and 72 hours post admission 
with an SAA concentration below 100 mg/l  
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Chapter Five: Conclusions and Future directions 
 
Being able to quantify serum amyloid A concentration in neonates using a point 
of care test allows veterinarians to obtain valuable information with regard to the health 
or disease status of a neonate in a rapid time frame, without requiring access to a 
laboratory. The studies described in this thesis expand our knowledge of serum amyloid 
A concentrations in both the healthy and sick neonate. The work of this thesis supports 
previous studies in this area and demonstrates that a point of care SAA test kit provides 
veterinarians with a useful tool when diagnosing disease in equine neonates.   The studies  
in this thesis demonstrate that limitations exist regarding using a point of care SAA test  
kit to diagnose disease in equine neonates. In order for this test to give the most insight  
into the occurring disease processes, the test needs to be executed once SAA  
concentrations have had ample time accumulate. Testing for SAA concentration too  
early (before 12 hours of age) may result in false negative results and misdirect a  
veterinarian's diagnosis. An alternative way to avoid this limitation is to continue to test  
SAA concentration as time progresses. 
 In follow up to the studies executed in this thesis, it would be beneficial for future 
studies in this area to focus on how to utilize a point of care serum amyloid A kit to 
monitor efficacy of treatment and convalescence of disease.  Also, knowing which cases 
to continue to monitor and how often to test serum amyloid A concentration in particular 
cases would offer valuable information to veterinarians.  Future studies in these areas 
would not only continue to improve diagnostic procedures, but would also advance 
equine neonatal disease management.  
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APPENDIX I 
 
LIST OF ABBREVIATIONS 
 
SAA……………………………………...………………………………Serum amyloid A 
 
CRP……………………………………………………………………C Reactive Protein 
 
WBC……………………………..………………………………………White Blood Cell 
 
TIA.……………………………..……………………………Turbidometric Immunoassay 
 
EIV……………………………..…………………………………..Equine Influenza Virus 
 
EHV-4……………………………………………………………. Equine Herpesvirus-4 
 
IAD………………………………………………….…….. Inflammatory Airway Disease 
 
SP-D…………………………………………………………………..Surfactant Protein D 
 
HIE……………………………………….……………Hypoxic Ischemic Encephalopathy  
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Appendix II: Foal Admission Form  
FOAL ADMISSIONFORM
PATIENT!NAME: DATE: TIME: WEIGHT:
CLINICIAN:
TECH!/!SUPERVISOR: SEX:!!!!!!!!COLT FILLY
HISTORY:
PHYSICAL!EXAMINATION: T: P: R: MM: CRT:
CV:
RESP:
GI:
MS: Cold.Extremities
OU:
UMB:
RESUSCITATION:
EPINEPHRINE: DOPRAM: DOBUTAMINE:.
NON>INVASIVE.RES: INTUBATED: AMBU.BAG: CHEST.COMPRESSIONS:
NOTES:
ULTRASOUND!NOTES:
SEDATION:
VALIUM: ML SAFE OTHER:
BUTORPHANOL: ML SAFE
CATHETER: TYPE!/!VEIN: RDVM!CATHETER!IN!PLACE:
OXYGEN!CANULA L/MIN:
INDWELLING!NGT:
UMBILICAL!DIP:
UMBILICAL!CLAMP
FECAL!/!S1
BLOODWORK!/!TESTING: CBC/C MP CR LYTES SAA
ACCU!CHECK LACTATE BLOOD!Cx ARD
ISTAT: TYPE:. ISTAT.RESULTS:
STUDY!BLOOD:
SURGERY: SURGEON!/!NOTES:
RADIOGRAPHS:
ENEMA: SOAPY RETENTION:
NOTES:
REFLUX!TUBE AMOUNT: TUBE!REMOVED
FLUIDS AMOUNT: TYPE:
ADDITIVES:
ADDITIONAL!ADMISSION!NOTES!AND!DRUGS:
MARE!TRANQ T: P: R:
COLOSTRUM VALUE: NI
MARE!NOTES:
DATE!/!TIME!OF!BIRTH:
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Appendix III: Dystocia Admission Form 
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Appendix IV: Data used in original study in Chapter 3 
Patient # Primary Diagnosis SAA Concentration, mg/l 
1 Colitis 0 
2 Colitis 0 
3 Colitis 5 
4 Colitis 32 
5 Colitis 65 
1 Colitis 68 
6 Colitis 88 
7 Colitis 677 
8 Colitis 1470 
9 Contracted  0 
10 Contracted  0 
11 Contracted  0 
12 Contracted  13 
13 Contracted  16 
14 Contracted  538 
15 Contracted  
16 Enteritis 0 
17 Enteritis 4 
18 Enteritis 46 
19 Enteritis 64 
20 Enteritis 108 
21 Enteritis 390 
22 Enteritis 517 
23 Enteritis 526 
24 Enteritis 619 
25 Enteritis 718 
26 Enteritis 2640 
28 HIE 0 
29 HIE 0 
30 HIE 0 
31 HIE 0 
32 HIE 0 
33 HIE 0 
34 HIE 0 
35 HIE 1 
36 HIE 11 
58	
37 HIE 13 
38 HIE 107 
39 HIE 167 
40 HIE 176 
41 HIE 225 
42 HIE 782 
43 HIE 953 
44 Normal 0 
45 Normal 0 
46 Normal 0 
47 Normal 0 
48 Normal 0 
49 Normal 0 
50 Normal 0 
51 Normal 0 
52 Normal 0 
53 Normal 0 
54 Normal 1 
55 Normal 34 
56 Normal 215 
57 Pneumonia 3 
58 Pneumonia 61 
59 Pneumonia 563 
60 Pneumonia 1023 
61 Pneumonia 1280 
62 Pneumonia 2387 
63 Pneumonia 2783 
64 Pneumonia 3899 
65 Pneumonia 4081 
66 Pneumonia 4724 
67 Premature 0 
68 Premature 0 
69 Premature 0 
70 Premature 0 
71 Premature 0 
72 Premature 0 
73 Premature 10 
74 Premature 45 
59	
75 Premature 46 
76 Sepsis 0 
77 Sepsis 6 
78 Sepsis 15 
79 Sepsis 43 
80 Sepsis 121 
81 Sepsis 238 
82 Sepsis 308 
3 Sepsis 324 
84 Sepsis 455 
85 Sepsis 565 
86 Sepsis 701 
87 sepsis 878 
88 Sepsis 1212 
89 Sepsis 1757 
90 Sepsis 1917 
91 Sepsis 2348 
92 Sepsis 3107 
93 Sepsis 4764 
94 Weak Foal 0 
95 Weak Foal 0 
96 Weak Foal 0 
97 Weak Foal 0 
98 Weak Foal 0 
99 Weak Foal 0 
100 Weak Foal 0 
101 Weak Foal 0 
102 Weak Foal 0 
103 Weak Foal 0 
104 Weak Foal 0 
105 Weak Foal 2 
106 Weak Foal 2 
107 Weak Foal 2 
108 Weak Foal 3 
109 Weak Foal 3 
110 Weak Foal 5 
111 Weak Foal 7 
112 Weak Foal 8 
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113 Weak Foal 9 
114 Weak Foal 14 
115 Weak Foal 23 
116 Weak Foal 26 
117 Weak Foal 32 
118 Weak Foal 34 
119 Weak Foal 40 
120 Weak Foal 59 
121 Weak Foal 70 
122 Weak Foal 83 
123 Weak Foal 198 
124 Weak Foal 849 
125 Weak Foal 1046 
126 Weak Foal 1106 
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Appendix V: Data used in original study in Chapter 4 
SAA Concentration mg/l 
Age 
at 
admit 
(hrs) 
Primary 
Diagnosis 
0 Hrs post 
admission 
12 Hrs 
post 
admission 
24 Hrs 
post 
admission 
48 Hrs 
post 
admission 
72 Hrs 
post 
admission 
0 
aspiration 
pneumonia  
6 523 836 1264 581 
0 
aspiration 
pneumonia  
5 354 385 802 143 
0 
aspiration 
pneumonia  
24 767 1123 1076 592 
0 
aspiration 
pneumonia  
44 677 2432 2679 2234 
0 
aspiration 
pneumonia 
84 1368 1135 1743 657 
0 
aspiration 
pneumonia  
42 2673 843 517 365 
0 
aspiration 
pneumonia  
41 162 136 41 0 
0 
aspiration 
pneumonia  
63 1243 1798 456 169 
48 gastrointestinal 3000 2784 2528 453 1186 
24 gastrointestinal 646 763 448 159 59 
48 gastrointestinal 760 1049 1228 1213 1169 
48 gastrointestinal 279 668 627 340 12 
12 gastrointestinal 1123 1895 2777 775 1642 
12 gastrointestinal 238 853 1173 1121 363 
0 gastrointestinal 0 566 677 190 17 
0 gastrointestinal 17 450 1544 2345 2206 
0 HIE 1 26 81 12 0 
0 HIE 0 324 689 566 317 
0 HIE 12 222 735 476 154 
0 HIE 53 420 482 169 51 
0 HIE 0 370 496 14 60 
0 HIE 3 141 304 118 26 
0 HIE 0 28 33 11 0 
0 HIE 0 229 61 171 142 
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Appendix VI: Diagnostic values for differentiating between infectious and non-
infectious disease as determined by the test manufacturer  
The diagnostic values for differentiating between infectious and non-infectious disease as 
determined by the test manufacturer were used to determine the threshold (100mg/l) that 
would indicate disease in the original studies in this thesis.  
SAA cut-off value  15 ug/ml 30 ug/ml 50 ug/ml 100 ug/ml 200 ug/ml 
Sensitivity 93 91.5 90.7 89.1 83.7 
Specificity 100 100 100 100 100 
Pos. Predictive 
Value 
100 100 100 100 100 
Neg. Predictive 
Value 
81.6 78.4 76.9 74.1 65.6 
Accuracy 94.7 93.5 92.9 91.7 87.6 
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